Literature DB >> 2427084

Folylpolyglutamate synthetase inhibition and cytotoxic effects of methotrexate analogs containing 2,omega-diaminoalkanoic acids.

J J McGuire, P Hsieh, C T Franco, J R Piper.   

Abstract

The properties of a series of methotrexate analogs containing 2,omega-diaminoalkanoic acids have been investigated. The compounds were potent inhibitors of dihydrofolate reductase but, unlike methotrexate, they were also inhibitors of mammalian folylpolyglutamate synthetases. The potency of synthetase and reductase inhibition increased with increasing length of the 2,omega-diaminoalkanoate moiety. The most cytotoxic compound and the most potent inhibitor of both dihydrofolate reductase (I50 = 2.5 to 4 nM) and folylpolyglutamate synthetase (Ki ca. 4 microM) contained 2,5-diaminopentanoic acid (ornithine). These compounds were 70- to 100-fold less cytotoxic than methotrexate to human leukemia cell lines; however, they retained their potency against sublines resistant to methotrexate via defective transport. Their dual loci of enzyme inhibition and their efficacy against methotrexate transport-defective cell lines indicate that these compounds may be an important new class of antifol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427084     DOI: 10.1016/0006-2952(86)90060-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

1.  Inhibition of human folylpolyglutamate synthetase by diastereomeric phosphinic acid mimics of the tetrahedral intermediate.

Authors:  John J McGuire; David M Bartley; John W Tomsho; William H Haile; James K Coward
Journal:  Arch Biochem Biophys       Date:  2009-06-27       Impact factor: 4.013

Review 2.  Exploitation of folate and antifolate polyglutamylation to achieve selective anticancer chemotherapy.

Authors:  J J McGuire; T Tsukamoto; B P Hart; J K Coward; T I Kalman; J Galivan
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.